Professor Radford has had a career long interest in Hodgkin and non-Hodgkin lymphoma. He has undertaken internationally leading research in the field most notably with respect to developing the evidence base for PET scan directed therapy in Hodgkin lymphoma. He took a leading role in the clinical development of brentuximab vedotin. He has a long association with the UK NCRI Lymphoma Clinical Studies Group and was chair from 2011-2017. He currently leads the NIHR Manchester Patient Safety Translational Research Centre’s theme on the oncology tertiary care/primary care interface.
He has a major interest in reducing late treatment toxicity especially in second cancers and in collaboration with Public Health England has led the development of a national database (BARD) of women at high risk of breast cancer following radiotherapy for lymphoma patients under the age of 36. He chairs the Centre for Living Beyond Cancer Science steering committee and is also leading several digital health projects. One of these, RAPID-digital, was recently designated a national exemplar by Health Data Research UK. He has published more than 400 academic papers, been cited in excess of 20,000 times, generated £13m in research funding over the last 5 years and given numerous invited talks most recently in the US and Europe.